CONFERENCE DAY ONE

7:30 am Check-In & Morning Coffee

8:20 am Chair’s Opening Remarks

Boosting Exosome & Extra-Cellular Vesicle Innovation & Clinical Strategy Towards the First Therapeutic Approval

8:30 am Clinical Application of Platelet-Derived Exosomes in Regenerative Medicine

Synopsis

  • Introduction to Rion’s exosome-based drug product and MOA
  • Current application of Rion’s technology in clinical trials
  • Forward-looking application of platelet-derived exosomes

NEW DATA!

9:00 am Accelerating Exosome-Based Therapeutics: From Innovation to GMP-Ready Solution

Synopsis

  • Showcasing an update on EXO Biologics’ clinical trials
  • Presenting exosomes use as a safer alternative to viral drug delivery systems
  • Ensuring the quality and compliance of your exosomes

NEW DATA!

9:30 am A Non-Conventional Pathway to Commercialize an EV Therapeutic

Synopsis

  • MSC secretome: Cell therapy without the cells
  • Navigating Direct Biologics’ pathway to phase III clinical trial
  • Leveraging nature’s mechanism of action for disease mitigation

NEW DATA!

10:00 am Morning Break & Networking

Synopsis

This session is your opportunity to get face-to-face with many of the brightest minds working in the exosome and extra-cellular vesicle therapy field, and establish meaningful business relationships to pursue for the rest of the conference

Advancing Clinical EV-Based Therapeutic Programs To Achieve Improved Safety & Mechanims of Action in Patients

11:00 am Update on Cleared US FDA IND for Acute Ischemic Stroke Using Neural Stem Cell Derived EVs

  • Steven Stice Co-Founder & Chief Scientific Officer, ArunA Bio

Synopsis

  • AB126: A first-in-class EV Therapy for stroke and CNS diseases and designed to treat stroke patients with poor prognosis post-reperfusion: A high medical-need
  • IND-cleared, with preliminary work underway for the first-in-human trial
  • AB126 offers a novel, multi-target solution with a clear mechanisms or action that address inflammation, immune response and repair

NEW DATA!

11:30 am Session Reserved for: Lonza

12:00 pm Clinical Advances in EV Therapies

Synopsis

  • Updating the field on Aegle’s therapeutic clinical progress
  • Highlighting where we go from here and overcoming key challenges

NEW DATA!

12:30 pm Lunch Break & Networking

Envisioning the Success of Exosome & Extra-Cellular Vesicles Therapies Enabled by Robust Biopharma Partnerships & Scientific Collaboration

1:30 pm Biopharma Leaders Panel Discussion: Unlocking the Next Wave of Safe & Efficient Exosome-Based Therapeutics Towards Clinical & Commercial Reality

Synopsis

This is your chance to hear from pioneering executive leaders from the exosome and extra-cellular vesicle community who will discuss their strategies, challenges, and future perspectives for exosome technology and clinically relevant therapeutic applications.

  • What are the future opportunities, promising targets, and applications on the horizon for exosomes to achieve clinical success?
  • What can we learn from past experiences, principles, and guidelines to roadmap and accelerate the next 5 years of therapeutic development?
  • What advice can you give this room of exosome experts to reduce risk, extend cash flow, and become an investable SME?

2:15 pm Advances in EV Manufacturing: Case Studies of Fully Automated Exosome Isolation Systems

  • Joseph Barendt Senior Director of Business Development, Daicel Life Sciences

Synopsis

  • Process improvements combining chromatography and TFF
  • Acceleration of clinical trial-scale process development
  • Focus on improved purity while maintaining high yield

2:45 pm Afternoon Break & Scientific Poster Session

Synopsis

As the discovery and development of exosomes and extra-cellular vesicle-based therapeutics continues to advance, it is essential to collaborate and share knowledge to streamline the approval process. Share your latest findings and gain insight into the cutting-edge work of your peers and promote collaboration.

Supercharging EV-Based Carrier Delivery to Ensure Efficient Targeting & Efficacious Translation Towards the Clinic

3:30 pm AI-Driven Natural Drug Delivery Platform Technology for Enhanced In Vivo Delivery

  • Inkyu Lee R&D Senior Researcher & Business Development Senior Manager, Shiftbio

Synopsis

  • Engineering Natural Nanoparticles (NNPs) using NNP Sorting Motif (NSM) for enhanced delivery
  • Understanding the dynamics of engineered NNP surface proteins to recognize specific target cell types
  • Elucidating the mechanism of NNP engineering through AI prediction

NEW DATA!

4:00 pm Unlocking the Potential of Multicolor EV Characterization with Flow NanoAnalyzer

Synopsis

  • Reviewing the state of the art in multi-color labeling of biological nanoparticles like EVsand discuss important choices in instrumentation configuration, reagent selection, and experimental design
  • The Flow Nanoanalyzer is a highly sensitive nano flow cytometry device designed specifically for the detection of nanoparticles and their associated dim fluorescent signals
  • Discussing calibration for size and count of EVs, quantifications of fluorescent signals, and common experimental factors that can impact sensitivity

4:10 pm Can Extracellular Vesicles be Engineered for Muscle Delivery?

Synopsis

  • Showcasing StealthX: Exosome-based platform for engineering of EVs
  • Harnessing a muscle-targeting moiety to improve muscle delivery in vitro and in vivo
  • Presenting possible applications of muscle-targeting EVs

NEW DATA!

4:40 pm Session Reserved for: Unchained Labs

4:50 pm MEVs (Microalgae Extracellular Vesicles) – A Universal Delivery System for RNA Therapeutics, Vaccines & Gene Therapies

Synopsis

  • Introducing MEVs and MEV technology
  • Showcasing the uniqueness of MEVs compared with mammalian EVs
  • Demonstrating MEV potential through data-driven case studies

NEW COMPANY!

5:20 pm Chair’s Closing Remarks

5:30 pm End of Conference Day One